 Regeneron Pharmaceuticals Inc. and Sanofi S.A. said they would begin a late-stage study of an experimental treatment for chronic eczema in hopes of gaining U.S. regulatory approval following mid-stage studies in which the drug significantly reduced patients' skin rashes and itchiness. . The drug, called dupilumab, is thought to treat the disease by blocking the body's allergic response to environmental antigens. Moderate to severe eczema, also known as atopic dermatitis, affects as many as one million people in the U.S., according...
  